Survival time according to the year of recurrence and subtype in recurrent XXXX .

@entity1 @entity0 @entity66 @entity109 @entity1722
BACKGROUND: Survival for @entity1 with recurrent @entity0 has improved over time due to the introduction of modern systemic therapy. The aim of this study was to determine the impact of subtype and the year of recurrence on the survival times of recurrent @entity0 . METHODS: Between 1979 and 2013, 813 @entity1 who underwent initial treatment for primary @entity0 experienced recurrence. They were divided into two groups based on the year of recurrence; before 2000 and after 2001. Survival after recurrence was compared between these groups based on following criteria; subtypes, @entity66 ( @entity66 ), and dominant recurrent site. The median follow-up period after recurrence was 4.3 years. RESULTS: Survival improved significantly in the after 2001 group, and a significant improvement in survival was only seen in the @entity1722 -enriched subtype. Multivariate analysis revealed that @entity66 , ER, @entity1722 status, dominant recurrent site and the Ki-67 index value were significant prognostic factors. In the @entity1722 -enriched subtype, the year of recurrence, @entity66 and dominant recurrent site were significant independent factors. In the other subtypes, these factors were not correlated with survival. CONCLUSION: Our study revealed that the survival rate of @entity1 with only the @entity1722 -enriched subtype significantly improved after recurrence. To prolong the survival time after recurrence of both @entity109 and triple negative subtypes, the development of novel targeting therapies to overcome refractory recurrent @entity0 is extremely important.
